OBJECTIVES: To examine patient perspectives on perceived value of medications used in moderate-to-severe psoriasis in the United States. METHODS: Online surveys and patient focus groups were conducted from a nationally representative psoriasis patient panel was conducted in April 2010. Respondents, aged ≥18 years old, were grouped as mild and moderate-to-severe psoriasis. Participants were asked to rate PsO severity based on palm rule where one palm is considered as covering 1% body surface area (BSA).  Participants were also asked about time to diagnosis, treatment history, monthly out-of-pocket treatment costs, and value of treatments.   RESULTS: Of the 1013 participants, 50% were male, and mean age was 49 years. Psoriasis disease severity was reported by 32% (n=321) as mild and 68% (n=692) as moderate-to-severe. Annual household income ranging from $25-75K was reported by 40% of participants. Over 70% had been diagnosed with psoriasis for ≥5years. Among those currently receiving prescription or over-the-counter psoriasis treatment (n=795), approximately one-third (mild=37%, moderate-severe=35%) reported very good/excellent value for their PsO treatment as compared to good (33% and 31%, respectively), fair (24%, 27%), and poor (6%, 8%). Patients receiving biologic or disease modifying anti-rheumatic drugs (DMARD) (47% and 52%, respectively) rated the value of their treatment as very good/excellent compared to other treatments, including light therapy. Those with out-of-pocket costs